GreenLight Biosciences- Warrants (30/09/2027) Profit Margin

GreenLight Biosciences- Warrants (30/09/2027) posts a profit margin of -1549.12% as of March 2023. That compares with -12584.61% in the prior-year period — up 87.7% year over year. That is below the sector sector average of 21.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, GreenLight Biosciences- Warrants (30/09/2027)'s profit margin was -12584.61%. The latest reading is -1549.12% — a 87.7% year-over-year increase (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 21.34% is typical. GreenLight Biosciences- Warrants (30/09/2027)'s -1549.12% is lower that level. That is roughly 7358.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

GreenLight Biosciences- Warrants (30/09/2027)'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -1549.12% as of March 2023; use YoY and peer views to separate noise from signal.

Context for GRNAW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.34%), and (3) consistency with growth and profitability. This page covers the first two; GreenLight Biosciences- Warrants (30/09/2027)'s other metric pages and overview cover the third.